BriaCell Therapeutics (NASDAQ:BCTX) Stock Price Down 4.6%

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX – Get Rating) traded down 4.6% during trading on Wednesday . The stock traded as low as $5.95 and last traded at $6.03. 101,680 shares changed hands during trading, a decline of 44% from the average session volume of 181,220 shares. The stock had previously closed at $6.32.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of BriaCell Therapeutics in a report on Friday, February 24th.

BriaCell Therapeutics Stock Performance

The firm has a market cap of $91.09 million, a PE ratio of -2.79 and a beta of 1.23. The company’s 50-day simple moving average is $6.93 and its two-hundred day simple moving average is $6.49.

Institutional Investors Weigh In On BriaCell Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in BriaCell Therapeutics during the 1st quarter valued at $77,000. Virtu Financial LLC purchased a new stake in BriaCell Therapeutics during the 2nd quarter valued at $60,000. Natixis purchased a new stake in shares of BriaCell Therapeutics in the 4th quarter worth about $56,000. HighTower Advisors LLC purchased a new stake in shares of BriaCell Therapeutics in the 1st quarter worth about $107,000. Finally, Apollon Wealth Management LLC lifted its position in shares of BriaCell Therapeutics by 12.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 17,900 shares of the company’s stock worth $101,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 16.34% of the company’s stock.

BriaCell Therapeutics Company Profile

(Get Rating)

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.